Home Trending Stocks 3 Best Gene Therapy Stocks for long-term Investment

3 Best Gene Therapy Stocks for long-term Investment

We are living in a modern world of technology. Gene Therapy is the new generation of the advanced medical sector. Let’s see the potential Gene stocks for investment.

The evolving cutting-edge science has given a new shape to the field of genetics, making impossible things possible. The development of mapping the human genome was the first step of unveiling the mystery behind genetics.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Today’s Gene Therapy firms are working on CRISPR technology. CRISPR is also known as clustered regularly interspaced short palindromic repeats. This technology fancies calculated genetic engineering that helps in the treatment of genetic disorders.

In the past few years, Gene Therapy firms have seen significant growth. The future awaits this market sector to boom, making gene therapy stocks a worthy investment in long-term growth.

Here are the three best gene therapy stocks for investment in the longer run.

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics (CRSP) is one of the leading gene therapy firms and is considered a long-term stock for investors. Two of the firm’s main candidates include CTX001 and CTX110, which makes CRISPR Therapeutics prominent in its respective space.

CTX001 helps in treating patients suffering from transfusion-dependent beta-thalassemia and sickle cell disease. Whereas, CRISPR’s CTX110 candidate is currently under its clinical trials which just obtained positive Phase 1 results in October 2020. CTX110 is being tested in treating patients with refractory non-Hodgkin lymphoma. These two candidates hold the future of the company in gene therapy.

CRISPR Therapeutics stock has soared over 245% since March 11, 2020. The stock has jumped from $43.28 to now trading at $150.49.

The majority of the analysts rate the CRSP stock as a buy. 11 of the Wall Street analysts have rated it as a buy, while 3 have rated it as a hold, and 2 sell ratings.

In the past three months, CRISPR Therapeutics has been published in 12 research reports, showing high interest of analysts towards the stock.

bluebird bio (BLUE)

bluebird bio (BLUE) shares are down by over 50% year-to-date. So, is it still a good buy?

The stock went down after the company faced production problems during the pandemic. bluebird wasn’t able to answer the FDA regarding its commercial manufacturing of a new treatment for sickle cell disease. The company was short on manufacturing capacity.

So, for this reason, bluebird bio (BLUE) will not be able to submit the FDA approval until 2022.

Things have been underwhelming for the gene therapy stock but the long-term growth seems evident. The fact is that the company will still be able to market its sickle cell disease treatment in Europe under the name Zynteglo. Moreover, bluebird has also obtained a priority review from the FDA for its multiple myeloma drug ide-cel. So, the overall portfolio looks good and the stock will have an upward movement in the longer run.

The company dominates the gene therapy market, with Bluebird bio (BLUE) having a market cap of just under $3 billion, pointing towards the long-term valuation for the investors.

bluebird bio has been under analysts’ radar and they have a strong interest in BLUE stock. Wall Street analysts rate bluebird bio stock as a buy.

Intellia Therapeutics (NTLA)

Intellia Therapeutics (NTLA) consists of a great team with the co-founder Jennifer Doudna, the pioneers of CRISPR technology. In 2012, Doudna was awarded a Nobel Prize in Chemistry for discovering CRISPR technology.

Intellia is working on its lead candidate, NTLA-2001, which is under Phase 1 trials. NTLA-2001 is an in vivo treatment for the genetic disease transthyretin amyloidosis. Moreover, the company has two other lead candidates including NTLA-2002 and NTLA-5001 that are ready for regulatory submission in 2021.

Intellia is well-designed to progress in gene therapy providing solutions to prominent genetic problems.

At the moment, 11 of the Wall Street analysts have passed their rating on NTLA stock, with 7 buy rating and 4 hold rating. So, it’s one gene therapy stock to look at in the long-term run.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why Is BTZI Stock Increasing Today?

The stock price of BOTS, Inc. (OTCPink: BTZI) has been rising more than 7% today and was buoying at $0.1266 at the last check....

Why Has The KBSF Stock Price Gained 10% In Last Session?

As of Friday's normal trading session, the price of KBS Fashion Group Limited (NASDAQ: KBSF) rose $0.26 or 9.96% to conclude at $2.87. KBS...

Why Royal Bank of Canada (RY) stock plummeted in after-hours on Friday?

Royal Bank of Canada (RY) stock lost 64.36% in the extended hour trading session on Friday, April 16, 2021. The RY stock gained merely...

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

Why Progyny Inc (PGNY) stock gained on Thursday, April 15?

Progyny Inc (PGNY) stock gained 7.31% in the after-hours session on Thursday, April 15, 2021, after it gained 0.94% in the early session.  PGNY...

Is This Why The APLD Stock Skyrocketed Last Trading?

Applied Science Products, Inc. (OTCPK: APLD) closed at $0.635 and experienced a 215.92% increase on Friday. A total of 2.07M shares of Applied Science...

The CRSS Stock Increased 82% In The Last Session Due To What?

Stock of Crossroads Systems, Inc. (OTCQX: CRSS) gained 81.82% or $18.00 in Friday's trading session, closing the day at $40.00 a share. Crossroads Systems...

How Did The ZVO Stock Appreciate 9% In The Last Trading Session?

Zovio Inc (NASDAQ: ZVO) normally sees about 413.34K shares traded on a regular business day but on a Friday it saw a bit higher...

Related News

Why Is BTZI Stock Increasing Today?

The stock price of BOTS, Inc. (OTCPink: BTZI) has been rising more than 7% today and was buoying at $0.1266 at the last check....

Why Has The KBSF Stock Price Gained 10% In Last Session?

As of Friday's normal trading session, the price of KBS Fashion Group Limited (NASDAQ: KBSF) rose $0.26 or 9.96% to conclude at $2.87. KBS...

Why Royal Bank of Canada (RY) stock plummeted in after-hours on Friday?

Royal Bank of Canada (RY) stock lost 64.36% in the extended hour trading session on Friday, April 16, 2021. The RY stock gained merely...

Why Did The CMCL Stock Rise By 8% In Last Trading?

Caledonia Mining Corporation Plc (NYSE: CMCL) gained 8.91% during the trading session on Thursday. The share price reached a low of $13.70 and a...

Why Progyny Inc (PGNY) stock gained on Thursday, April 15?

Progyny Inc (PGNY) stock gained 7.31% in the after-hours session on Thursday, April 15, 2021, after it gained 0.94% in the early session.  PGNY...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.